RxDoctor Payments Data

Sindhu Basil

Acute Care · Dallas, TXNPI 1467932343

Payments from drug & device makers

$1,459in general payments, 2019–2025

Across 25 payments — averaging $58.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$632
  • BD$146
  • Medtronic$140
  • BETA Bionics, Inc.$120
  • GRT US Holding, Inc.$119
  • Lilly USA, LLC$118
  • plus $185 from 3 others

What the payments were for

  • Food & beverage$1,459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,459 in reported general payments places this provider in the 75th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$32,370
Medicare patients
200
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$51,831
MounjaroTirzepatide41$45,329
JardianceEmpagliflozin32$33,235
TrulicityDulaglutide22$26,430
TradjentaLinagliptin13$12,973
Novolog FlexpenInsulin Aspart24$5,782
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$4,439
Humalog Kwikpen U-100Insulin Lispro16$3,501
Humulin N KwikpenInsulin Nph Human Isophane30$3,062
Ultra-Fine Short Pen NeedlePen Needle, Diabetic33$2,946
Insulin Lispro Kwikpen U-100Insulin Lispro16$2,764
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic12$1,606
Insulin Aspart FlexpenInsulin Aspart11$1,416
Metformin Hcl23$255
Metformin Hcl ErMetformin Hcl13$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$118$71,75963 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,323 acute care providers in Texas.

Other acute care in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →